MS
CRSP icon

Monetary Solutions’s CRISPR Therapeutics CRSP Stock Holding History

Monetary Solutions’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36K Hold
80
– – ﹤0.01% 248
2026
Q1 		$3.81K Hold
80
– – ﹤0.01% 246
2025
Q4 		$4.2K Buy
+80
New +$4.79K ﹤0.01% 233

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Monetary Solutions's CRSP Position: Q2 2026 in Review

Monetary Solutions held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 80 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #248.

Monetary Solutions first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 401 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Monetary Solutions held 80 shares of CRISPR Therapeutics worth $4.36K as of Q2 2026.
  • Monetary Solutions left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Monetary Solutions's portfolio in Q2 2026, its #248 holding.
  • Monetary Solutions first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 401 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Monetary Solutions's 13F filing for Q2 2026, filed 23 Jul 2026.